Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin

Acta Haematologica

Volumn 101, Issue 1, 1999, Pages 53-55

  Brennand, Janet E ^a,c   Walker, Isobel D ^b   Greer, Ian A ^a  

^a Glasgow Royal Maternity Hospital ^*  (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c QUEEN MOTHER S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING INHIBITOR; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; MATERNAL MORTALITY; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; PRIORITY JOURNAL; TERATOGENESIS; THROMBOEMBOLISM;

EID: 0033058272     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040922     Document Type: Article

References (12)

1. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1991-93. London, HMSO, 1996.
2. Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E: Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992;340: 152-156.
3. Bara L, Billaud E, Gramond G, Kher A, Samama M: Comparative pharmacokinctics of low molecular weight heparin (PK10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39:631-636.
4. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
5. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7-11.
6. Hirsh J, Ofosu FA, Levine M: The development of low molecular weight heparins for clinical use: in Verstraete M, Vermylen J, Lijnen R, Arnout J (eds): Thrombosis and Haemostasis, Leuven, Leuven University Press, 1987, pp 325-348.
7. Aiach M, Michaud A, Balian J-L, Lefebvre M, Woler M, Fourtillan J: A new low molecular weight heparin derivative. In vitro and in vivo studies. Thromb Res 1983;31:611-621.
8. Turpie AGG, Levine MN, Hirsch J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M: A randomised controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315:925-929.
9. Brace LD, Fareed J: An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 1985; 11:190.
10. Gillis S, Shushan A, Eldor A: Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynecol Obstet 1992;39:297-301.
11. Nelson-Piercy C, Letsky EA, DeSwiel M: Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience in sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062-1068.
12. Boneu B: Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330-334.